Abstract
It is necessary to explore new targets for the treatment of colon adenocarcinoma (COAD) according to the tumor microenvironment. The expression levels of JAML and CXADR were analyzed by bioinformatics analysis and validation of clinical samples. JAML over-expression CD8+ T cell line was constructed, and the proliferation activity was detected by MTT. The production of inflammatory factors was detected by ELISA. The expression of immune checkpoint PD-1 and TIM-3 was detected by Western blot. The apoptosis level was detected by flow cytometry and apoptosis markers. The AOM/DSS mouse model of colorectal cancer was constructed. The expression levels of JAML, CXADR and PD-1 were detected by PCR and Western blot, and the proportion of CD8+ T cells and exhausted T cells were detected by flow cytometry. The expression levels of JAML and CXADR were significantly decreased in colon cancer tissues. Overexpression of JAML can promote the proliferation of T cells, secrete a variety of inflammatory factors. Overexpression of CXADR can reduce the proliferation of colorectal cancer cells, promote apoptosis, and down-regulate the migration and invasion ability of tumor cells. Both JAML agonists and PD-L1 inhibitors can effectively treat colorectal cancer, and the combined use of JAML agonists and PD-L1 inhibitors can enhance the effect. JAML can promote the proliferation and toxicity of CD8+ T cells and down-regulate the expression of immune checkpoints in colon cancer. CXADR can inhibit the proliferation of cancer cells and promote the apoptosis. JAML agonist can effectively treat colorectal cancer by regulating CD8+ T cells.
Similar content being viewed by others
Data availability
Data to support the findings of this study is available on reasonable request from the corresponding author.
References
Albini A, Bruno A, Gallo C et al (2015) Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. Connect Tissue Res 56(5):414–425
Benson AB, Venook AP, Al-Hawary MM et al (2018) NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw 16(4):359–369
Bergelson JM, Cunningham JA, Droguett G et al (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275(5304):1320–1323
Curran MA, Montalvo W, Yagita H et al (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 107(9):4275–4280
Eschweiler S, Wang A, Ramírez-Suástegui C et al (2023) JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells [published online ahead of print, 2023 Jan 25]. Cell Rep 42(2):112040
Fu Y, Sun Y, Wang M et al (2020) Elevation of JAML promotes diabetic kidney disease by modulating podocyte lipid metabolism. Cell Metab 32(6):1052-1062.e8
Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964
Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14(10):1014–1022
Hadrup S, Donia M, Thor SP (2013) Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenviron 6(2):123–133
Huang K, Ru B, Zhang Y et al (2019) Sertoli cell–specific coxsackievirus and adenovirus receptor regulates cell adhesion and gene transcription via β-catenin inactivation and Cdc42 activation [published correction appears in FASEB J. 2019 Aug;33(8):9695]. FASEB J 33(6):7588–7602
Huang W, Wang BO, Hou YF et al (2022) JAML promotes acute kidney injury mainly through a macrophage-dependent mechanism. JCI Insight 7(14):e158571
Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501(7467):346–354
Kim JE, Hong YS, Kim HJ et al (2015) Defective mismatch repair status was not associated with DFS and OS in stage II colon cancer treated with adjuvant chemotherapy. Ann Surg Oncol 22(Suppl 3):S630–S637
Kumar A, Gautam V, Sandhu A et al (2023) Current and emerging therapeutic approaches for colorectal cancer: a comprehensive review. World J Gastrointest Surg 15(4):495–519
Lai CT, Chi CW, Wu SH et al (2022) Midostaurin modulates tumor microenvironment and enhances efficacy of Anti-PD-1 against colon cancer. Cancers (Basel) 14(19):4847
Li J, Xu X (2023) Immune checkpoint inhibitor-based combination therapy for colorectal cancer: an overview. Int J Gen Med 16:1527–1540
McGraw JM, Thelen F, Hampton EN et al (2021) JAML promotes CD8 and γδ T cell antitumor immunity and is a novel target for cancer immunotherapy. J Exp Med 218(10):e20202644
Nilchian A, Johansson J, Ghalali A et al (2019) CXADR-mediated formation of an AKT inhibitory signalosome at tight junctions controls epithelial-mesenchymal plasticity in breast cancer. Can Res 79:47–60
Overman MJ, Lonardi S, Wong KYM et al (2018) Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36(8):773–779
Philipson L, Pettersson RF (2004) The coxsackie-adenovirus receptor–a new receptor in the immunoglobulin family involved in cell adhesion. Curr Top Microbiol Immunol 273:87–111
Raskov H, Orhan A, Christensen JP et al (2021) Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer 124(2):359–367
Roh SE, Jeong Y, Kang MH et al (2018) Junctional adhesion molecules mediate transendothelial migration of dendritic cell vaccine in cancer immunotherapy. Cancer Lett 434:196–205
Siegel RL, Miller KD, Goding Sauer A et al (2020) Colorectal cancer statistics, 2020. CA Cancer J Clin 70(3):145–164
Stecker K, Vieth M, Koschel A et al (2011) Impact of the coxsackievirus and adenovirus receptor on the adenoma-carcinoma sequence of colon cancer. Br J Cancer 104:1426–1433
Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
Wang C, Zhang H, Liu Y et al (2023) Molecular subtyping in colorectal cancer: a bridge to personalized therapy (Review). Oncol Lett 25(6):230
Whiteside TL (2008) The tumor microenvironment and its role in promoting tumor growth. Oncogene 27(45):5904–5912
Wu Q, Li R, Wang QX et al (2022) Junctional adhesion molecule-like protein promotes tumor progression via the Wnt/β-catenin signaling pathway in lung adenocarcinoma. J Transl Med 20(1):260
Wu Q, Wang YB, Che XW et al (2023) Junctional adhesion molecule-like protein as a novel target for kaempferol to ameliorate lung adenocarcinoma. J Integr Med 21(3):268–276
Zhang Y, Lui WY (2023) CXADR: from an essential structural component to a vital signaling mediator in spermatogenesis. Int J Mol Sci 24(2):1288
Funding
This research work received supports from the Shandong Province Medical and Health Technology Development Plan Project (No. 202211000867), Outstanding Young Talents Project of Shandong Provincial Third Hospital (No. jqrc002) and Shandong Provincial Third Hospital Cultivation Fund Project (No. M2023002).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
All authors declare that there are no conflicts of interest.
Supplementary Information
Below is the link to the electronic supplementary material.
Supplementary Figure 1
Bright-field and fluorescence images of control and JAML overexpression groups. Scale bars = 50 μm (PNG 180 kb)
Supplementary Figure 2
The expression levels of 3 extracellular matrix glycoproteins. (A) The expression levels of fibronectin (FN1), laminin-1 (LAMB1) and tenascin-R (TNR) in normal and tumor tissues by TCGA database. (B) The expression levels of fibronectin (FN1), laminin-1 (LAMB1) and tenascin-R (TNR) were measured by western blot in CXADR-overexpressed and control HT29 cells (PNG 51.9 kb)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Cheng, S., Li, M., Li, C. et al. JAML inhibits colorectal carcinogenesis by modulating the tumor immune microenvironment. In Vitro Cell.Dev.Biol.-Animal (2024). https://doi.org/10.1007/s11626-024-00881-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11626-024-00881-8